Increased confidence of M356 approval starting to be reflected in the share price. Baxter's management team is showing increased interest in MNTA's capabilities and would like to acquire the company if M356 is approved.
we can;t discount the implications of the July to September court decision that is due regarding their patent infringement and their opportunity to enter the market with product in 2014 vs 2015.
That possibility has huge implications and should contribute to a justified run up in stock price, I believe there is a justifiable 25% upside from here as we approach that milestone. The stock should trade at 19 here.